Evidence map›Paper›PMID 29506940›Full record

ArticleUrologic oncology2018

Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.

Nicolas von Landenberg, Atiqullah Aziz, Friedrich C von Rundstedt, Jakub Dobruch, Luis A Kluth, Andrea Necchi, Aidan Noon, Michael Rink, Kees Hendricksen, Karel P J Decaestecker and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Urologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Nicolas von LandenbergDepartment of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany.
Atiqullah AzizDepartment of Urology, University of Rostock, Rostock, Germany.
Friedrich C von RundstedtDepartment of Urology, Jena University Hospital, Friedrich-Schiller- University, Jena, Germany.
Jakub DobruchDepartment of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Luis A KluthDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andrea NecchiDepartment of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Aidan NoonDepartment of Urology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.
Michael RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kees HendricksenDepartment of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Karel P J DecaesteckerDepartment of Urology, Ghent University Hospital, Ghent, Belgium.
Roland SeilerDepartment of Urology, University of Bern, Bern, Switzerland.
Cédric PoyetDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Harun FajkovicDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Evanguelos XylinasDepartment of Urology, Cochin Hospital, Assistance-Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.
Florian RoghmannDepartment of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: f.roghmann@gmail.com.
Young Academic Urologists′ Working Group on Urothelial Cancer of the European Association of Urology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine conditional recurrence-free survival (RFS) and progression-free survival (PFS) and improve decision-making toward surveillance protocols and scheduling. Furthermore, evaluating the evolution of predictors for disease recurrence over time, because TaG1 non-muscle-invasive bladder cancer harbors a risk of disease recurrence and progression. MATERIAL AND

methodsThe retrospective multicenter design study includes 1,245 TaG1 bladder cancer patients with median follow-up of 62.7 (interquartile range: 34.3-91.1) months. Conditional RFS and PFS estimates were calculated using the Kaplan-Meier method. Multivariable Cox regression model was calculated proportional for the prediction of recurrence and progression (covariables: age, tumor size, multiple tumors, prior recurrence, and immediate postoperative instillation of chemotherapy).

resultsAfter 3 months without event, the conditional RFS and PFS (to ≥pT2) rates for 5 additional years without event were 57.5% and 93.4%, respectively. Given a 1-, 2-, 3-, and 5-year survival, the conditional RFS rates for 5 additional years without event improved by +9.8 (67.3%), +5.2 (72.5%), +6.5 (79.0%), +2.0 (81.0%), and +1.0% (82.0%), respectively. In contrast, the 5-year conditional PFS rates were more or less stable with 94.3% after 1 year to 94.1% after 5 years. Multivariable analyses showed decreasing impact of risk parameters on RFS estimates over time. Based on these findings, we suggest a risk stratification to individualize follow-up for intermediate risk TaG1. Main limitation was the retrospective design.

conclusionsConditional-survival analyses demonstrates that the patient risk profile changes over time. RFS rates rise with increasing survival whereas PFS rates were stable. The impact of prognostic features decreases over time. Our findings can be used for patient counseling and planning of personalized follow-up.

Indexed as

AgedDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesRisk FactorsSurvival RateUrinary Bladder NeoplasmsBladder cancerConditional analysisNon–muscle invasiveRecurrence and progressionUrothelial carcinoma

Identifiers

PMID29506940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.